To access this element change to forms mode OFF
Grant Award View - GA259019
Accelerating clot lysis in ischemic stroke with dornase alfa in an...
GA ID:
GA259019
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Mar-2022
Publish Date:
25-Jul-2022
Category:
Medical Research
Grant Term:
1-Jul-2022 to 30-Jun-2026
Value (AUD):
$1,453,336.70
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Clinical Trials and Cohort Studies
Grant Activity:
Accelerating clot lysis in ischemic stroke with dornase alfa in an Umbrella Bayesian Optimised Phase 2 trial
Purpose:
Stroke remains a major cause of disability. Clot-dissolving medicines targeting fibrin can be rapidly delivered at most Australian hospitals. DNA extruded by white blood cells is another key structural component of clot. Dornase, an approved medicine for other diseases, dissolves DNA and we showed accelerated clot dissolving when combined with standard treatment. Our trial will test whether dornase can accelerate restoration of blood flow to improve outcomes in up to 300 patients with stroke.
GO ID:
GO Title:
NHMRC Clinical Trials and Cohort Studies Grants 2021 for funding mid-2022
Internal Reference ID:
2022/GNT2015100
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, VIC
Postcode:
Multiple
Country:
AUSTRALIA